The Centers for Medicare & Medicaid Services (CMS) Medicaid Integrity Group (MIG) has identified issues with the utilization of the atypical antipsychotic drug therapy class. The U.S. Food and Drug Administration (FDA) approves product labeling for prescription drugs. The MIG has identified that some providers may have prescribed atypical antipsychotics outside of FDA-approved product labeling for indication, age, dosage, or duration of therapy. Therefore, CMS’s goal is to improve quality of care and enhance patient safety by educating providers on the proper use of atypical antipsychotics in adults.

This fact sheet summarizes for providers the current FDA-approved product labeling for the use of atypical antipsychotic medications in adults. After reading this document, the provider should be able to accurately:

- Describe the FDA-approved indications for the use of atypical antipsychotics in adult patients;
- Formulate treatment regimens that comply with FDA-approved product labeling; and
- Describe the adverse reactions and risks associated with atypical antipsychotic therapy in adult patients.

**FDA-Approved Adult Indications for Atypical Antipsychotics**

Atypical antipsychotics, or second-generation antipsychotics (SGAs), are dopamine receptor antagonists that may also antagonize norepinephrine and serotonin (5-HT) receptors to varying degrees. The FDA-approved adult indications for atypical antipsychotics are summarized in Table 1 below. The FDA-approved adult indications and dosages for atypical antipsychotics are provided in the dosing tables in the document “Atypical Antipsychotics: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Adults.”
Table 1. FDA-Approved Adult Indications for Atypical Antipsychotics

<table>
<thead>
<tr>
<th>Indications</th>
<th>Atypical Antipsychotics</th>
</tr>
</thead>
<tbody>
<tr>
<td>bipolar I disorder</td>
<td>aripiprazole, asenapine, olanzapine, quetiapine, quetiapine extended-release (XR), risperidone, ziprasidone</td>
</tr>
<tr>
<td>schizophrenia</td>
<td>aripiprazole, asenapine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, quetiapine XR, risperidone, ziprasidone</td>
</tr>
<tr>
<td>schizoaffective disorder</td>
<td>clozapine, paliperidone</td>
</tr>
<tr>
<td>major depressive disorder (MDD), adjunct</td>
<td>aripiprazole, olanzapine, quetiapine XR</td>
</tr>
</tbody>
</table>

Treatment Guidelines for the Use of Atypical Antipsychotics in Adults

The Agency for Healthcare Research and Quality (AHRQ) hosts a database of treatment guidelines. Please search “atypical antipsychotics,” or any of the conditions for which an atypical antipsychotic is an indicated treatment, in the AHRQ’s National Guideline Clearinghouse at http://www.guideline.gov for information on the available treatment guidelines. Links to several of the guidelines that provide information on the use of atypical antipsychotics in adults are provided in Table 2 below.

Table 2. Treatment Guidelines for the Use of Atypical Antipsychotics in Adults

<table>
<thead>
<tr>
<th>Sponsoring Organization</th>
<th>Title of Guideline</th>
<th>Link to Guideline</th>
</tr>
</thead>
</table>

The Schizophrenia Patient Outcomes Research Team (PORT) has published treatment recommendations for the use of atypical antipsychotics by patients with schizophrenia. Information on the PORT recommendations can be found at http://www.ahrq.gov/clinic/schzrec.htm on the AHRQ website.
Time to Symptom Improvement with an Atypical Antipsychotic

Many patients will experience relief of some symptoms within a few days of starting treatment with an atypical antipsychotic, but the full effects of the medication may not be seen for up to six weeks. Agitation and hallucinations are typically relieved during the first few days of treatment, but it may take weeks for delusions to subside. Every patient responds differently to antipsychotic therapy, so it may take several trials of different antipsychotic medications to find the one that works best. The titration schedule of the medication may also influence the length of time it takes to see symptom improvement: a medication that takes two weeks to reach the recommended dose may require a longer trial than a medication that takes less than a week to reach the recommended dose.

If a patient does not achieve the desired clinical response, the dose of the atypical antipsychotic may need to be increased or the medication may need to be changed to a different antipsychotic medication. Treatment guidelines can provide guidance when a change in therapy is warranted. Factors for switching medication therapy include:

- Lack of efficacy;
- Lack of improvement in negative symptoms;
- Presence of extrapyramidal side effects (EPS) or adverse reactions impacting adherence to therapy; and
- Cost of therapy.

If a patient does not achieve the desired clinical response, patient adherence to therapy should be assessed prior to increasing dosage, switching to a different antipsychotic, or prescribing an additional medication. If the patient has had trouble complying with treatment in the past, a long-acting injectable medication may be the best option. The patient should still be evaluated for symptom improvement during the effective duration of the long-acting injectable medication to assess its efficacy.

Off-Label Use of Atypical Antipsychotics in Adults

An AHRQ report titled “Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics” was published in 2007. In September 2011, the AHRQ released an update titled “Off-Label Use of Atypical Antipsychotics: An Update.” After the 2007 report was published, studies for off-label indications were published and previous off-label indications were approved by the FDA. Safety and efficacy were evaluated, and a summary of the findings for each off-label indication is provided in the 2011 update. Links to the 2007 report and the 2011 update are available at http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=778&PCem=EN on the AHRQ website.
Adverse Reactions and Risks of the Use of Atypical Antipsychotics in Adults

Patients should be made aware of the risks of taking an atypical antipsychotic prior to initiating therapy. Because atypical antipsychotic medications are associated with significant weight gain and metabolic changes, a baseline weight, blood glucose level, and lipid panel should be established and then monitored. Other common adverse reactions are:

- Drowsiness;
- Orthostatic hypotension;
- Tachycardia;
- Menstrual problems;
- Blurred vision;
- Sun sensitivity; and
- Skin rash.18

Risk of Suicidality

The atypical antipsychotics aripiprazole, olanzapine, quetiapine, and quetiapine XR are FDA-approved for the treatment of depression episodes in bipolar I disorder or as adjunctive treatment for MDD. Antidepressant medications have been shown to increase the risk of suicidal thinking and behavior. In a pooled-analysis of short-term, placebo-controlled trials of nine antidepressant medications, patients taking an antidepressant had twice the risk of suicidality in the first few months of treatment than those taking placebo. The long-term risk is unknown. As a result of this analysis, a boxed warning was added to all antidepressant medications since the risk was not confined to one class of antidepressants.19

The FDA requires that a Medication Guide be provided with each prescription for aripiprazole, olanzapine, quetiapine, and quetiapine XR to alert patients to the risk of suicidal thinking and behavior. Each Medication Guide includes information on precautions that may be taken. Links to the required Medication Guides can be found at http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm on the FDA website.

Use in Elderly Patients with Dementia

In 2005, the FDA issued a public health advisory to alert consumers and providers that atypical
antipsychotics have been associated with increased mortality when used to treat behavioral disorders in elderly patients with dementia. The advisory states: “Of a total of seventeen placebo controlled trials performed with olanzapine (Zyprexa®), aripiprazole (Abilify®), risperidone (Risperdal®), or quetiapine (Seroquel®) in elderly demented patients with behavioral disorders, fifteen showed numerical increases in mortality in the drug-treated group compared to the placebo-treated patients. These studies enrolled a total of 5,106 patients, and several analyses have demonstrated an approximately 1.6 to 1.7 fold increase in mortality in these studies. Examination of the specific causes of these deaths revealed that most were either due to heart related events (e.g., heart failure, sudden death) or infections (mostly pneumonia).”

None of the atypical antipsychotic medications are FDA approved for this indication. A “Boxed Warning” has been added to product labeling to describe this increased risk of mortality and to note that atypical antipsychotics are not approved for this indication.

Risk of Serious Allergic Reactions with Asenapine

On September 1, 2011, the FDA published a Drug Safety Communication to alert the public to the risk of serious allergic reactions with asenapine. The allergic reactions are Type I hypersensitivity reactions that may include anaphylaxis, angioedema, difficulty breathing, hypotension, rash, swollen tongue, tachycardia, or wheezing. Patients should be counseled on the signs and symptoms of an allergic reaction, and should be instructed to seek immediate medical attention if signs or symptoms occur.

Post-Injection Delirium and Sedation with Olanzapine Pamoate Injection

Olanzapine pamoate injection is a long-acting atypical antipsychotic. It has been associated with delirium and sedation, typically seen in a patient with an olanzapine overdose. Because of the severity of this potential adverse reaction, olanzapine pamoate injection may only be given in a registered healthcare facility, is only available through a restricted distribution program, and may not be dispensed directly to the patient.
Clozapine Warnings

Clozapine has been associated with agranulocytosis, seizures, myocarditis, and orthostatic hypotension. It has also been linked to respiratory arrest and cardiac arrest in patients taking benzodiazepines or other psychotropic drugs. The FDA-required boxed warnings for clozapine address these serious adverse reactions.\textsuperscript{26, 27}

The boxed warning for olanzapine pamoate injection states:\textsuperscript{25}

**WARNING: POST-INJECTION DELIRIUM/SEDATION SYNDROME**

Post-Injection Delirium/Sedation Syndrome—Adverse events with signs and symptoms consistent with olanzapine overdose, in particular, sedation (including coma) and/or delirium, have been reported following injections of ZYPREXA RELPREVV. ZYPREXA RELPREVV must be administered in a registered healthcare facility with ready access to emergency response services. After each injection, patients must be observed at the healthcare facility by a healthcare professional for at least 3 hours. Because of this risk, ZYPREXA RELPREVV is available only through a restricted distribution program called ZYPREXA RELPREVV Patient Care Program and requires prescriber, healthcare facility, patient, and pharmacy enrollment [see Dosage and Administration (2.1), Warnings and Precautions (5.1, 5.2), Overdosage (10.2), and Patient Counseling Information (17.2)].

The boxed warning for all clozapine products states:\textsuperscript{28}

**BOXED WARNING**

1. Agranulocytosis

Because of a significant risk of agranulocytosis, a potentially life-threatening adverse event, CLOZARIL\textsuperscript{®} (clozapine) should be reserved for use in (1) the treatment of severely ill patients with schizophrenia who fail to show an acceptable response to adequate courses of standard antipsychotic drug treatment, or (2) for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at risk of reexperiencing suicidal behavior.

Patients being treated with clozapine must have a baseline white blood cell (WBC) count and absolute neutrophil count (ANC) before initiation of treatment as well as regular WBC counts and ANCs during treatment and for at least 4 weeks after discontinuation of treatment (see WARNINGS).

Clozapine is available only through a distribution system that ensures monitoring of WBC count and ANC according to the schedule described below prior to delivery of the next supply of medication (see WARNINGS).

2. Seizures

Seizures have been associated with the use of clozapine. Dose appears to be an important predictor of seizure, with a greater likelihood at higher clozapine doses. Caution should be used when administering clozapine to patients having a history of seizures or other predisposing factors. Patients should be advised not to engage in any activity where sudden loss of consciousness could cause serious risk to themselves or others (see WARNINGS).

3. Myocarditis

Analyses of postmarketing safety databases suggest that clozapine is associated with an increased risk of fatal myocarditis, especially during, but not limited to, the first month of therapy. In patients in whom myocarditis is suspected, clozapine treatment should be promptly discontinued (see WARNINGS).
4. Other Adverse Cardiovascular and Respiratory Effects
Orthostatic hypotension, with or without syncope, can occur with clozapine treatment. Rarely, collapse can be profound and be accompanied by respiratory and/or cardiac arrest. Orthostatic hypotension is more likely to occur during initial titration in association with rapid dose escalation. In patients who have had even a brief interval off clozapine, i.e., 2 or more days since the last dose, treatment should be started with 12.5 mg once or twice daily. (See WARNINGS and DOSAGE AND ADMINISTRATION.)

Since collapse, respiratory arrest and cardiac arrest during initial treatment has occurred in patients who were being administered benzodiazepines or other psychotropic drugs, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug (see WARNINGS).

Due to the increased risk of agranulocytosis in a patient treated with clozapine, manufacturers of clozapine are required by the FDA to maintain a clozapine registry to monitor a patient’s white blood cell (WBC) count and absolute neutrophil count (ANC) throughout the course of treatment with clozapine. Novartis, the manufacturer of Clozaril®, is also responsible for maintaining a “non-rechallenge database” for patients who should not be rechallenged with clozapine due to the increased health risks associated with the medication. Manufacturers of generic clozapine must cross-reference a patient’s name against the non-rechallenge database and must provide information about a patient who should be added to this database.29 Links to the clozapine registries are provided in Table 3 below.

Table 3. Links to Clozapine Registries

<table>
<thead>
<tr>
<th>Medication</th>
<th>Manufacturer</th>
<th>Link to Registry</th>
</tr>
</thead>
<tbody>
<tr>
<td>FazaClo®</td>
<td>AzurPharma, Ltd.</td>
<td><a href="https://www.fazacloregistry.com">https://www.fazacloregistry.com</a></td>
</tr>
<tr>
<td>clozapine</td>
<td>Caraco Pharmaceutical Laboratories, Ltd.</td>
<td><a href="https://www.caracoclozapine.com">https://www.caracoclozapine.com</a></td>
</tr>
<tr>
<td>clozapine</td>
<td>Teva Pharmaceuticals USA</td>
<td><a href="http://www.clozapineregistry.com">http://www.clozapineregistry.com</a></td>
</tr>
</tbody>
</table>
Resources

Please visit http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-State/By-State.html for links to State Medicaid program websites.

The Center for Drug Evaluation and Research (CDER) hosts a website providing health professionals with current information on over-the-counter (OTC) and prescription drugs. Visit http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals to access drug-related databases, information on drug recalls and alerts, current information on new and generic drug approvals, and information on drug safety and availability.

Section 1927(g)(1)(B) of the Social Security Act identifies the predetermined standards that the State’s drug use review program must use to assess data on drug use. Visit http://www.ssa.gov/OP_Home/ssact/title19/1927.htm for information on the compendia.

References

Disclaimer

This fact sheet was current at the time it was published or uploaded onto the web. Medicaid and Medicare policies change frequently, so links to the source documents have been provided within the document for your reference.

This fact sheet was prepared as a service to the public and is not intended to grant rights or impose obligations. This fact sheet may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. Use of this material is voluntary. Inclusion of a link does not constitute CMS endorsement of the material. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.

May 2012

This fact sheet was prepared by the Education Medicaid Integrity Contractor for the CMS Medicaid Integrity Program (MIP). For more information on the MIP, please visit http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/MedicaidIntegrityProgram/Medicaid-Integrity-Provider-Education-Program.html on the CMS website.